Clinical efficacy of gemcitabine and cisplatin-based transcatheter arterial chemoembolization combined with radiotherapy in hilar cholangiocarcinoma.
Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine, cisplatin, and S-1: report of a case.
Angela Lamarca, MD, PhD, on Biliary Tract Cancers: Active Symptom Control With Oxaliplatin and Fluorouracil
Angela Lamarca, MD, PhD, of The Christie NHS Foundation Trust and the University of Manchester, discusses phase III findings from a multicenter study of active symptom control alone or active symptom control with oxaliplatin and fluorouracil for patients with locally advanced or metastatic biliary tract cancers previously treated with cisplatin and gemcitabine (Abstract 4003).
This is the abstract here –
Thanks to Melinda for bringing this up.
Hello! Have been reading through a lot of posts on here and am grateful for the input of everybody.
My Dad (78) was diagnosed with a Klatskin tumor in November 2018. Had the tumour and lobe of liver removed, margins were not clear.
He ended up back in hospital with a serious infection due to bile leakage and a pigtail drain was inserted with the hope that leakage would subside. This hasn’t happened and he still has a drain 6 months later. (Has been changed a few times) Surgeon says leak is from where they joined everything during resection surgery (sorry for lack of technical terms in all my explanations 😬😬) Surgeon says he can’t operate to repair leak as it’s too dangerous. We don’t really understand why.
Dad has 6 weeks radiation at the start of the year then a month off and began chemo – Gemcitabine cisplatin – at the end of March. He has only managed 3 or 4 treatments (can’t remember) so far as he keeps getting infections. This latest infection has been the worst so far. He is currently in hospital being treated with antibiotics for a Pseudomonas aeruginosa infection in his blood, plus having albumin, blood and platelet transfusions. He’s had nearly 20 litres drained from his abdomen over the last few days.
I’m just wondering if anyone has any similar experiences, or any advice.
Oncologist was due to do a scan after 2 more chemo sessions which would be roughly about now but I’m not sure what his plans are now. It’s hard coz we are not at the hospital when he talks to the oncologist.
Dad said they are going to test the fluid drained from the abdomen which I really hope is the case.
Anyway, I don’t have any direct questions as such….just wanted to get it all down in print and have a bit of solidarity I think.
Debbie (49 year old daughter)
This is Mims1924’s husband and this is our fist post. We had our first meeting with an oncologist yesterday. Initial diagnosis was based on jaundice and nausea and vomiting and abdomenal pain. Had one CT and two ERCPs, stents in both sides branches of the bile duct into the liver. Brushings and FNAs don’t provide any info. Mass looks like Katskin tumor, with suspiciously enlarged lymph nodes nearby. No definitive pathology, so there’s another CT scan today (MRI’s not an option for us) and then a laparoscopic procedure hopefully in 5 days to get a definitive tissue sample. Plan for treatment is IV gemcitabine + cisplatin, then radiation + capecitabine pill. Some number of cycles (3 I think). Surgery to remove the tumor and any affected lymph nodes. Suggested that this could cure it. For a second opinion, the Mayo Clinic and MD Anderson are the two that I hear the most.
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Impact on gemcitabine plus cisplatin in unresectable hilar cholangiocarcinoma patients according to effective biliary drainage: A multicenter study.
Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract CancersA Phase 2 Clinical Trial
Thanks to American Medical Association for this piece.
A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas.
The study is divided into two parts: single agent FT-2102 followed by combination therapy.
Part 1: A single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dose confirmation followed by a Phase 2 investigation of clinical activity in up to 4 cohorts. During the dose confirmation, additional doses or altered dose schedules may be explored.
Part 2: An open-label study of FT-2102 in combination with other anti-cancer agents. Patients will be enrolled across 4 different disease cohorts, examining the effect of FT-2102 + azacitidine (glioma and chondrosarcoma), FT-2102+nivolumab (hepatobiliary tumors) and FT-2102+gemcitabine/cisplatin (intrahepatic cholangiocarcinoma). There will be a safety lead-in followed by a Phase 2 evaluation in up to four cohorts of patients.
Viewing 15 results - 1 through 15 (of 586 total)
Viewing 15 results - 1 through 15 (of 586 total)